CG Oncology Inc · Q2 2026 earnings

Briefing

CG Oncology Inc reported Q2 2026 financial results on August 6, 2026, showing a net loss of $79.1 million amid ongoing clinical development.

CG Oncology, a clinical-stage biopharmaceutical company, reported minimal revenue of $1.2 million for the quarter ended June 30, 2026, primarily from commercial and development activities. The company posted a net loss of $79.1 million ($0.90 per share) and held $1.03 billion in cash, cash equivalents, and marketable securities, sufficient to fund operations through 2029. Key progress included publication of Phase 3 study results and anticipation of topline data from PIVOT-006.

• Net loss widened to $79.1 million ($0.90 EPS) from $41.4 million ($0.54 EPS) in Q2 2025 due to increased R&D and G&A expenses.
• Cash position stood at $1.03 billion as of June 30, 2026, supporting operations through 2029.
• R&D expenses rose to $54.7 million and G&A to $29.0 million, driven by clinical trials, CMC costs, and headcount growth.
• Company advanced pipeline with Lancet Oncology publication of BOND-003 data and expects BLA submission in Q4 2026.

Headline financials

Revenue & EPS history

Company anticipates PIVOT-006 Phase 3 topline data in the near-term, BLA completion for HR BCG-unresponsive NMIBC in Q4 2026, and additional durability data from multiple cohorts.